Prescreening | Screening/ Baselinea | Randomization | TAU/XR-BUP Initiation | Date of Discharge | Follow-Up | As Needed | |||
---|---|---|---|---|---|---|---|---|---|
DAY | 0 | 34 | 90 | 180 | |||||
General measures | |||||||||
Prescreen Approach Log | X | ||||||||
Verbal Consent | X | ||||||||
Prescreening Form | X | ||||||||
Written Informed Consent and Quiz | X | ||||||||
Inclusion/Exclusion | X | ||||||||
Locator Form | X | X | X | ||||||
PhenX [30] Core Tier 1 Forms | X | ||||||||
Demographics Forms | X | ||||||||
Treatment Satisfaction Survey | X | ||||||||
Treatment Initiation and Non-Initiation | X | ||||||||
Hospitalization MOUD | X | ||||||||
Marijuana Use Assessment | X | ||||||||
COVID-19 Impact Assessment | X | X | X | X | |||||
Timeline Followback (TLFB) (Medications) | X | X | X | ||||||
Study Completion Form | X | ||||||||
Measure of Primary and Secondary Outcomes | |||||||||
Engagement in MOUD Post Hospital Discharge | X | X | X | ||||||
Hospitalization and ED Utilization (Related or Not to OUD) | X | X | X | ||||||
Urine Drug Screen | X | X | X | X | |||||
X | X | X | X | ||||||
Clinical and safety assessments | |||||||||
Medical and Psychiatric History | X | ||||||||
Physical Examination | X | ||||||||
Injection Site Examinationb | X | X | |||||||
Injection Site Reaction Formc | X | X | X | ||||||
Hospitalization Diagnoses | X | ||||||||
Medical Comorbidity [33] | X | ||||||||
Vital Signs | X | ||||||||
DSM-5 Checklist [35] | X | ||||||||
Mental Health Follow-Up Assessment | X | ||||||||
Adverse Events, Including Serious Adverse Events | Xd | X | X | X | X | Xe | |||
Prior and Concomitant Medications | X | X | X | X | |||||
Clinical Opioid Withdrawal Scaleb; f [34] | X | ||||||||
Clinical laboratory assessments | |||||||||
Pregnancy and Birth Control Assessmentg | X | ||||||||
Confirmed Pregnancy and Outcome | X | ||||||||
Liver Transaminases (AST and ALT)h | X | ||||||||
Hepatitis B, Hepatitis C, HIV Antibodyh | X | X | |||||||
Genetic Samplingh | X | X | X | X | X | ||||
Family Origin | X | ||||||||
Exploratory measures | |||||||||
Healthcare and Services Utilization [36] | X | X | X | ||||||
Pain Assessment [37] | X | X | X | X | |||||
Depression (PHQ-9) [38] | X | X | X | X | |||||
Post-Traumatic Stress Disorder (PC-PTSD-5) [39] | X | X | X | X | |||||
Quality of Life (WHOQOL-BREF) [40] | X | X | |||||||
Non-Fatal Opioid Overdose | X | X | X | X | |||||
Fatal Opioid Overdose (collected on SAE form) | Xd | X | X | X | X | X | |||
Addiction Severity Index-Lite (ASI-Lite) Drug and Alcohol Use [41] | X | X | |||||||
Post-Hospitalization Medical Appointment Follow-Up | X | X | |||||||
Antibiotic Adherence for OUD-Related Infectionsi | X | X | |||||||
Hospital Length of Stay | X | X | X | X | |||||
Subsequent XR-BUP Injections (XR-BUP group only) | X | X | X | ||||||
Receipt of Other MOUD | X | X | X | ||||||
Administrative forms | |||||||||
Protocol Deviations | X | ||||||||
Missed Visit and Visit Documentation Form | X | X | X | X | X |